| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 100 | 2024 | 5317 | 10.810 |
Why?
|
| Brain Neoplasms | 26 | 2024 | 4849 | 3.820 |
Why?
|
| Skin Neoplasms | 35 | 2023 | 4654 | 3.810 |
Why?
|
| Immunotherapy | 42 | 2024 | 3341 | 2.450 |
Why?
|
| Ipilimumab | 19 | 2023 | 710 | 2.420 |
Why?
|
| Proto-Oncogene Proteins B-raf | 20 | 2023 | 1283 | 2.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 15 | 2022 | 1048 | 2.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 19 | 2023 | 3251 | 2.030 |
Why?
|
| Sarcoma | 10 | 2023 | 1725 | 1.880 |
Why?
|
| Radiosurgery | 6 | 2024 | 1330 | 1.590 |
Why?
|
| Neoplasms, Second Primary | 8 | 2022 | 1350 | 1.540 |
Why?
|
| Oximes | 8 | 2023 | 175 | 1.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 33 | 2023 | 15862 | 1.250 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2023 | 882 | 1.160 |
Why?
|
| Humans | 156 | 2024 | 261506 | 1.020 |
Why?
|
| Calcium Carbonate | 2 | 2013 | 28 | 0.950 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 6 | 2022 | 992 | 0.930 |
Why?
|
| Imidazoles | 7 | 2022 | 999 | 0.900 |
Why?
|
| Sarcoma, Synovial | 2 | 2018 | 119 | 0.900 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2022 | 502 | 0.860 |
Why?
|
| CTLA-4 Antigen | 9 | 2022 | 657 | 0.830 |
Why?
|
| B7-H1 Antigen | 5 | 2022 | 1022 | 0.830 |
Why?
|
| Protein Kinase Inhibitors | 15 | 2023 | 4757 | 0.810 |
Why?
|
| Neoplasms | 22 | 2023 | 15193 | 0.800 |
Why?
|
| Cancer Vaccines | 7 | 2023 | 697 | 0.790 |
Why?
|
| Antineoplastic Agents | 16 | 2021 | 14289 | 0.780 |
Why?
|
| Pyridones | 7 | 2023 | 348 | 0.770 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2020 | 14 | 0.750 |
Why?
|
| Pyrimidinones | 6 | 2023 | 314 | 0.750 |
Why?
|
| Hypoparathyroidism | 1 | 2020 | 49 | 0.730 |
Why?
|
| Hypocalcemia | 1 | 2020 | 59 | 0.720 |
Why?
|
| Autoantibodies | 2 | 2020 | 576 | 0.700 |
Why?
|
| Biomarkers, Tumor | 13 | 2022 | 10331 | 0.700 |
Why?
|
| Combined Modality Therapy | 12 | 2024 | 8865 | 0.680 |
Why?
|
| Standard of Care | 2 | 2020 | 243 | 0.680 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2019 | 170 | 0.680 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2022 | 5178 | 0.670 |
Why?
|
| Piperazines | 3 | 2019 | 2101 | 0.660 |
Why?
|
| Antibodies, Monoclonal | 11 | 2022 | 4367 | 0.660 |
Why?
|
| Phthalazines | 2 | 2019 | 253 | 0.650 |
Why?
|
| Neoplasm Metastasis | 11 | 2020 | 5112 | 0.630 |
Why?
|
| Lip Neoplasms | 1 | 2017 | 18 | 0.620 |
Why?
|
| Molecular Targeted Therapy | 9 | 2022 | 2330 | 0.610 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 246 | 0.610 |
Why?
|
| Interleukin-2 | 2 | 2018 | 842 | 0.600 |
Why?
|
| Pyrimidines | 4 | 2020 | 3518 | 0.580 |
Why?
|
| Health Care Costs | 1 | 2022 | 674 | 0.570 |
Why?
|
| Hepatitis C | 2 | 2023 | 524 | 0.570 |
Why?
|
| Antigens, Neoplasm | 7 | 2023 | 1506 | 0.560 |
Why?
|
| Male | 60 | 2023 | 123000 | 0.540 |
Why?
|
| Antineoplastic Agents, Immunological | 7 | 2022 | 1249 | 0.520 |
Why?
|
| T-Lymphocytes | 7 | 2023 | 3869 | 0.500 |
Why?
|
| Aged | 42 | 2022 | 70117 | 0.500 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 280 | 0.480 |
Why?
|
| Food-Drug Interactions | 1 | 2013 | 22 | 0.470 |
Why?
|
| Antacids | 1 | 2013 | 29 | 0.470 |
Why?
|
| Middle Aged | 46 | 2023 | 86204 | 0.460 |
Why?
|
| Biphenyl Compounds | 2 | 2014 | 194 | 0.460 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2015 | 612 | 0.460 |
Why?
|
| Pyridines | 4 | 2018 | 1244 | 0.450 |
Why?
|
| Female | 61 | 2023 | 141928 | 0.440 |
Why?
|
| Adult | 44 | 2022 | 77950 | 0.440 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 698 | 0.440 |
Why?
|
| Benzimidazoles | 4 | 2022 | 428 | 0.430 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2023 | 371 | 0.420 |
Why?
|
| Medulloblastoma | 2 | 2014 | 540 | 0.420 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2022 | 1763 | 0.410 |
Why?
|
| Antiviral Agents | 2 | 2023 | 1230 | 0.400 |
Why?
|
| Benzamides | 2 | 2013 | 1832 | 0.390 |
Why?
|
| Lymphoma | 1 | 2019 | 1467 | 0.390 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2014 | 272 | 0.390 |
Why?
|
| Dasatinib | 3 | 2021 | 862 | 0.370 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2014 | 488 | 0.370 |
Why?
|
| Neoadjuvant Therapy | 9 | 2023 | 4975 | 0.370 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 11538 | 0.370 |
Why?
|
| Heart Transplantation | 1 | 2017 | 908 | 0.370 |
Why?
|
| Aged, 80 and over | 24 | 2022 | 29902 | 0.360 |
Why?
|
| Dendritic Cells | 3 | 2021 | 1085 | 0.360 |
Why?
|
| Tertiary Lymphoid Structures | 2 | 2020 | 33 | 0.360 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2023 | 907 | 0.340 |
Why?
|
| Bone Neoplasms | 3 | 2017 | 2576 | 0.340 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 3022 | 0.340 |
Why?
|
| Dietary Supplements | 1 | 2013 | 558 | 0.340 |
Why?
|
| Neoplasm Staging | 17 | 2022 | 13658 | 0.340 |
Why?
|
| Tumor Microenvironment | 9 | 2023 | 2864 | 0.330 |
Why?
|
| Consensus | 5 | 2023 | 978 | 0.330 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2013 | 1756 | 0.330 |
Why?
|
| Liver Transplantation | 1 | 2017 | 1112 | 0.330 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2014 | 1678 | 0.330 |
Why?
|
| Mutation | 12 | 2023 | 15179 | 0.330 |
Why?
|
| ErbB Receptors | 2 | 2008 | 2295 | 0.320 |
Why?
|
| Treatment Outcome | 22 | 2023 | 32848 | 0.320 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2008 | 79 | 0.310 |
Why?
|
| Survival Analysis | 7 | 2022 | 9180 | 0.310 |
Why?
|
| Disease Progression | 8 | 2023 | 6682 | 0.300 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 3230 | 0.300 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 4549 | 0.290 |
Why?
|
| Prognosis | 14 | 2024 | 21713 | 0.290 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 4638 | 0.290 |
Why?
|
| Young Adult | 17 | 2021 | 21445 | 0.290 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2019 | 3890 | 0.280 |
Why?
|
| Drug Administration Schedule | 6 | 2019 | 3472 | 0.280 |
Why?
|
| Maximum Tolerated Dose | 4 | 2019 | 1290 | 0.280 |
Why?
|
| Survival Rate | 10 | 2022 | 12221 | 0.280 |
Why?
|
| Disease-Free Survival | 11 | 2021 | 10001 | 0.270 |
Why?
|
| Administration, Oral | 5 | 2019 | 1544 | 0.270 |
Why?
|
| Meningeal Neoplasms | 2 | 2020 | 441 | 0.260 |
Why?
|
| Azetidines | 2 | 2022 | 87 | 0.250 |
Why?
|
| Patient Selection | 4 | 2019 | 2055 | 0.250 |
Why?
|
| Medical Oncology | 7 | 2023 | 1423 | 0.250 |
Why?
|
| MAP Kinase Kinase Kinases | 3 | 2020 | 190 | 0.250 |
Why?
|
| Cross-Over Studies | 3 | 2016 | 460 | 0.240 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2023 | 1586 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2021 | 6207 | 0.240 |
Why?
|
| B-Lymphocytes | 2 | 2020 | 1294 | 0.240 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 14889 | 0.230 |
Why?
|
| Sulfonamides | 3 | 2019 | 1823 | 0.230 |
Why?
|
| Chordoma | 3 | 2016 | 163 | 0.220 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2021 | 299 | 0.220 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2023 | 1215 | 0.220 |
Why?
|
| Confidence Intervals | 3 | 2021 | 756 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 10035 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2019 | 986 | 0.210 |
Why?
|
| Piperidines | 3 | 2022 | 1035 | 0.210 |
Why?
|
| Drug Therapy, Combination | 3 | 2023 | 2315 | 0.200 |
Why?
|
| Neurofibromatosis 1 | 1 | 2023 | 144 | 0.200 |
Why?
|
| Retrospective Studies | 8 | 2023 | 37905 | 0.200 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 112 | 0.200 |
Why?
|
| Dietary Fiber | 1 | 2021 | 123 | 0.200 |
Why?
|
| Arthritis | 1 | 2022 | 139 | 0.200 |
Why?
|
| Tubulin | 1 | 2021 | 169 | 0.190 |
Why?
|
| Exanthema | 2 | 2020 | 211 | 0.190 |
Why?
|
| Antigens, CD | 2 | 2022 | 1385 | 0.190 |
Why?
|
| Pemphigoid, Bullous | 1 | 2020 | 24 | 0.190 |
Why?
|
| Drug Resistance | 1 | 2022 | 587 | 0.190 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 447 | 0.190 |
Why?
|
| Adolescent | 12 | 2022 | 31252 | 0.180 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 264 | 0.180 |
Why?
|
| Double-Blind Method | 2 | 2023 | 2588 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 152 | 0.180 |
Why?
|
| Lymphopenia | 1 | 2022 | 199 | 0.180 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2019 | 13 | 0.180 |
Why?
|
| Cranial Irradiation | 1 | 2021 | 315 | 0.180 |
Why?
|
| Carbamates | 1 | 2019 | 77 | 0.180 |
Why?
|
| Receptors, OX40 | 1 | 2019 | 50 | 0.170 |
Why?
|
| Central Nervous System | 1 | 2022 | 436 | 0.170 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2019 | 101 | 0.170 |
Why?
|
| HT29 Cells | 1 | 2019 | 159 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2022 | 479 | 0.170 |
Why?
|
| Probiotics | 1 | 2021 | 228 | 0.170 |
Why?
|
| Biomedical Research | 2 | 2023 | 806 | 0.160 |
Why?
|
| Paclitaxel | 3 | 2023 | 1996 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2015 | 588 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 1547 | 0.160 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 93 | 0.160 |
Why?
|
| Imatinib Mesylate | 2 | 2013 | 1665 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2021 | 349 | 0.160 |
Why?
|
| Brassica | 1 | 2018 | 19 | 0.160 |
Why?
|
| Enterocolitis | 1 | 2018 | 43 | 0.160 |
Why?
|
| DNA Modification Methylases | 2 | 2010 | 172 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Xanthomatosis | 1 | 2018 | 21 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2020 | 607 | 0.160 |
Why?
|
| Infliximab | 1 | 2018 | 130 | 0.160 |
Why?
|
| HCT116 Cells | 1 | 2019 | 348 | 0.160 |
Why?
|
| Fever | 1 | 2021 | 497 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 1248 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 4938 | 0.160 |
Why?
|
| Isothiocyanates | 1 | 2018 | 44 | 0.160 |
Why?
|
| Histiocytes | 1 | 2018 | 94 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2021 | 419 | 0.160 |
Why?
|
| Gold | 1 | 2020 | 270 | 0.160 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 108 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 2403 | 0.160 |
Why?
|
| Hepatitis C, Chronic | 1 | 2023 | 451 | 0.160 |
Why?
|
| Rare Diseases | 1 | 2021 | 351 | 0.160 |
Why?
|
| Pyrrolidines | 1 | 2018 | 113 | 0.150 |
Why?
|
| DNA Repair Enzymes | 2 | 2010 | 237 | 0.150 |
Why?
|
| Nevus | 1 | 2018 | 107 | 0.150 |
Why?
|
| Liver Function Tests | 1 | 2017 | 173 | 0.150 |
Why?
|
| MCF-7 Cells | 1 | 2019 | 550 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 672 | 0.150 |
Why?
|
| Vaccines | 1 | 2022 | 389 | 0.150 |
Why?
|
| Anemia | 1 | 2023 | 689 | 0.150 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 3719 | 0.150 |
Why?
|
| United States | 5 | 2023 | 15433 | 0.150 |
Why?
|
| Leiomyosarcoma | 2 | 2015 | 223 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2019 | 333 | 0.150 |
Why?
|
| Area Under Curve | 2 | 2021 | 700 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 573 | 0.150 |
Why?
|
| Interferon-alpha | 2 | 2019 | 889 | 0.150 |
Why?
|
| Mycophenolic Acid | 1 | 2017 | 148 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2022 | 878 | 0.140 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2019 | 604 | 0.140 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2018 | 355 | 0.140 |
Why?
|
| Models, Theoretical | 1 | 2021 | 785 | 0.140 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2016 | 44 | 0.140 |
Why?
|
| Indazoles | 1 | 2018 | 297 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2018 | 215 | 0.140 |
Why?
|
| Dioxoles | 1 | 2015 | 19 | 0.140 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2016 | 75 | 0.130 |
Why?
|
| Scalp | 1 | 2017 | 156 | 0.130 |
Why?
|
| Drug Delivery Systems | 2 | 2012 | 669 | 0.130 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2015 | 24 | 0.130 |
Why?
|
| Steroids | 1 | 2017 | 356 | 0.130 |
Why?
|
| Quinolones | 1 | 2016 | 160 | 0.130 |
Why?
|
| Membrane Proteins | 2 | 2018 | 2819 | 0.130 |
Why?
|
| Biopsy | 3 | 2018 | 3443 | 0.130 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2015 | 104 | 0.130 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2019 | 368 | 0.130 |
Why?
|
| Cohort Studies | 7 | 2021 | 9244 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 544 | 0.130 |
Why?
|
| Proteomics | 2 | 2020 | 1380 | 0.130 |
Why?
|
| Oncolytic Viruses | 1 | 2017 | 204 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 860 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 1382 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 852 | 0.120 |
Why?
|
| Chondrosarcoma | 1 | 2016 | 216 | 0.120 |
Why?
|
| Smoothened Receptor | 1 | 2014 | 52 | 0.120 |
Why?
|
| Animals | 11 | 2022 | 59536 | 0.120 |
Why?
|
| Monitoring, Immunologic | 1 | 2014 | 47 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 2594 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 848 | 0.120 |
Why?
|
| Receptor, EphA2 | 1 | 2014 | 132 | 0.120 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2014 | 111 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 726 | 0.120 |
Why?
|
| Loss of Heterozygosity | 1 | 2015 | 602 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 8873 | 0.120 |
Why?
|
| Liposarcoma | 1 | 2015 | 214 | 0.120 |
Why?
|
| Calcium, Dietary | 1 | 2013 | 56 | 0.120 |
Why?
|
| Triazoles | 1 | 2018 | 617 | 0.110 |
Why?
|
| Pneumonia | 1 | 2019 | 751 | 0.110 |
Why?
|
| Creatinine | 1 | 2015 | 531 | 0.110 |
Why?
|
| Half-Life | 1 | 2013 | 259 | 0.110 |
Why?
|
| Dacarbazine | 1 | 2015 | 485 | 0.110 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 1555 | 0.110 |
Why?
|
| Intestinal Absorption | 1 | 2013 | 211 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3981 | 0.110 |
Why?
|
| Quality of Life | 5 | 2024 | 4532 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2015 | 639 | 0.110 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 424 | 0.100 |
Why?
|
| Antigens, Differentiation | 2 | 2019 | 238 | 0.100 |
Why?
|
| Indoles | 1 | 2017 | 1009 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2013 | 553 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 1146 | 0.100 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 342 | 0.100 |
Why?
|
| Patient Safety | 1 | 2017 | 649 | 0.100 |
Why?
|
| Cancer Care Facilities | 2 | 2018 | 884 | 0.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 833 | 0.100 |
Why?
|
| Signal Transduction | 5 | 2017 | 11965 | 0.100 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 6009 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 1375 | 0.100 |
Why?
|
| Phenotype | 3 | 2020 | 6295 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2010 | 1823 | 0.100 |
Why?
|
| Transcriptome | 2 | 2020 | 1859 | 0.090 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2013 | 261 | 0.090 |
Why?
|
| Hydroxamic Acids | 1 | 2013 | 442 | 0.090 |
Why?
|
| Dendritic Cells, Follicular | 2 | 2020 | 38 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2017 | 3005 | 0.090 |
Why?
|
| Cerebellar Neoplasms | 1 | 2014 | 434 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2012 | 479 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2018 | 1533 | 0.090 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 1664 | 0.090 |
Why?
|
| Italy | 2 | 2021 | 236 | 0.090 |
Why?
|
| Gastritis | 1 | 2013 | 373 | 0.090 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2021 | 160 | 0.090 |
Why?
|
| Apoptosis | 2 | 2017 | 7591 | 0.090 |
Why?
|
| Gastric Mucosa | 1 | 2013 | 613 | 0.090 |
Why?
|
| Radiation Injuries | 1 | 2017 | 1411 | 0.090 |
Why?
|
| Brain | 2 | 2022 | 4113 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2020 | 2967 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2021 | 1033 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 1688 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2012 | 649 | 0.080 |
Why?
|
| Carboplatin | 2 | 2023 | 823 | 0.080 |
Why?
|
| DNA Mismatch Repair | 1 | 2010 | 268 | 0.080 |
Why?
|
| Nausea | 2 | 2022 | 525 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2010 | 365 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 2390 | 0.080 |
Why?
|
| Choroid Neoplasms | 1 | 2008 | 41 | 0.080 |
Why?
|
| Capsules | 2 | 2018 | 53 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2326 | 0.080 |
Why?
|
| Mice | 7 | 2022 | 34495 | 0.080 |
Why?
|
| Biological Therapy | 1 | 2007 | 58 | 0.080 |
Why?
|
| Oxides | 1 | 2008 | 211 | 0.070 |
Why?
|
| Rituximab | 1 | 2012 | 1528 | 0.070 |
Why?
|
| Arsenicals | 1 | 2008 | 201 | 0.070 |
Why?
|
| Clone Cells | 2 | 2020 | 555 | 0.070 |
Why?
|
| Child | 4 | 2019 | 29154 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2020 | 7548 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 2 | 2022 | 651 | 0.070 |
Why?
|
| Hospitals, Pediatric | 1 | 2011 | 773 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2023 | 12873 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2012 | 840 | 0.070 |
Why?
|
| Societies, Medical | 2 | 2023 | 1335 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 787 | 0.070 |
Why?
|
| Kidney | 1 | 2015 | 2146 | 0.070 |
Why?
|
| Critical Care | 1 | 2012 | 770 | 0.070 |
Why?
|
| Incidence | 3 | 2021 | 5673 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 6942 | 0.070 |
Why?
|
| Drug Eruptions | 2 | 2018 | 256 | 0.070 |
Why?
|
| Genes, ras | 1 | 2008 | 667 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2015 | 7226 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 311 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2022 | 1144 | 0.060 |
Why?
|
| Cetuximab | 1 | 2005 | 472 | 0.060 |
Why?
|
| Biomarkers | 3 | 2023 | 5047 | 0.060 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 14551 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2017 | 2947 | 0.060 |
Why?
|
| Hip Joint | 1 | 2003 | 54 | 0.060 |
Why?
|
| Sustained Virologic Response | 1 | 2023 | 57 | 0.060 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2023 | 34 | 0.060 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2023 | 52 | 0.060 |
Why?
|
| G(M2) Ganglioside | 1 | 2022 | 2 | 0.060 |
Why?
|
| Injection Site Reaction | 1 | 2022 | 9 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 211 | 0.050 |
Why?
|
| Viremia | 1 | 2023 | 177 | 0.050 |
Why?
|
| Calcitonin | 1 | 2003 | 186 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2008 | 1245 | 0.050 |
Why?
|
| Receptors, Death Domain | 1 | 2022 | 7 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 52 | 0.050 |
Why?
|
| DNA Repair | 1 | 2010 | 1872 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 2283 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 5159 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 3976 | 0.050 |
Why?
|
| Platinum | 1 | 2022 | 138 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2016 | 1021 | 0.050 |
Why?
|
| Ecosystem | 1 | 2022 | 111 | 0.050 |
Why?
|
| MART-1 Antigen | 1 | 2021 | 105 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2021 | 2218 | 0.050 |
Why?
|
| Pyrrolidinones | 1 | 2021 | 61 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 342 | 0.050 |
Why?
|
| Antigen Presentation | 1 | 2022 | 272 | 0.050 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2021 | 149 | 0.050 |
Why?
|
| Osteoporosis | 1 | 2003 | 241 | 0.050 |
Why?
|
| Quinazolines | 1 | 2005 | 923 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2023 | 397 | 0.050 |
Why?
|
| Databases, Nucleic Acid | 1 | 2020 | 117 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 37 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2022 | 358 | 0.050 |
Why?
|
| Interleukin-1beta | 1 | 2021 | 300 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 5395 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3821 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2014 | 5270 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 709 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2C8 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 4844 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 225 | 0.040 |
Why?
|
| Metabolic Flux Analysis | 1 | 2019 | 27 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 368 | 0.040 |
Why?
|
| Drug Stability | 1 | 2019 | 105 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 406 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2022 | 493 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2019 | 100 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2022 | 657 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2019 | 83 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2020 | 760 | 0.040 |
Why?
|
| Sulfoxides | 1 | 2018 | 22 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2019 | 176 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 15694 | 0.040 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2019 | 86 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 441 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 278 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 770 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 309 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 383 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 709 | 0.040 |
Why?
|
| Gonanes | 1 | 2017 | 45 | 0.040 |
Why?
|
| Risk Factors | 3 | 2020 | 17523 | 0.040 |
Why?
|
| Biological Availability | 1 | 2018 | 214 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2020 | 374 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2019 | 548 | 0.040 |
Why?
|
| Linear Models | 1 | 2021 | 1085 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2019 | 355 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 253 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 1183 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2021 | 938 | 0.040 |
Why?
|
| Adenine | 1 | 2020 | 631 | 0.040 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 224 | 0.040 |
Why?
|
| Phosphoramide Mustards | 1 | 2017 | 37 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 702 | 0.040 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2017 | 72 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2018 | 259 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 272 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 98 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 733 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2016 | 49 | 0.040 |
Why?
|
| Nitroimidazoles | 1 | 2017 | 100 | 0.040 |
Why?
|
| Tablets | 1 | 2016 | 53 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2016 | 70 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2018 | 280 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2018 | 875 | 0.040 |
Why?
|
| Stomatitis | 1 | 2017 | 183 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 470 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1304 | 0.030 |
Why?
|
| Dogs | 1 | 2018 | 1155 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2020 | 6869 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 503 | 0.030 |
Why?
|
| Seizures | 1 | 2022 | 989 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 344 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2022 | 1048 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 242 | 0.030 |
Why?
|
| Registries | 1 | 2023 | 2170 | 0.030 |
Why?
|
| Necrosis | 1 | 2017 | 580 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 435 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2020 | 1152 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1987 | 0.030 |
Why?
|
| Pain | 1 | 2003 | 1658 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2021 | 1171 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 4988 | 0.030 |
Why?
|
| Time Factors | 3 | 2021 | 12926 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2022 | 1959 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2020 | 2450 | 0.030 |
Why?
|
| Freund's Adjuvant | 1 | 2013 | 43 | 0.030 |
Why?
|
| Diarrhea | 1 | 2018 | 686 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2014 | 162 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 149 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2017 | 829 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2013 | 107 | 0.030 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2013 | 59 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2023 | 6100 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2015 | 575 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 376 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 598 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 1052 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 182 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 81 | 0.030 |
Why?
|
| Genome | 1 | 2017 | 672 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 1439 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 235 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2292 | 0.030 |
Why?
|
| Skin | 1 | 2018 | 1259 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2015 | 341 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 4298 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 995 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 1489 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2020 | 1471 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 1165 | 0.030 |
Why?
|
| Fatigue | 1 | 2018 | 1239 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 1130 | 0.020 |
Why?
|
| Alleles | 1 | 2017 | 2437 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2019 | 4307 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 1742 | 0.020 |
Why?
|
| Genomics | 1 | 2022 | 2738 | 0.020 |
Why?
|
| Proteome | 1 | 2014 | 561 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 1516 | 0.020 |
Why?
|
| Lipids | 1 | 2013 | 644 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2014 | 1152 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 6086 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 2015 | 929 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 1271 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 3438 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 2466 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3033 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 2054 | 0.020 |
Why?
|
| Texas | 1 | 2018 | 6311 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 2927 | 0.020 |
Why?
|
| Skull | 1 | 2007 | 231 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7222 | 0.020 |
Why?
|
| Models, Biological | 1 | 2014 | 3254 | 0.020 |
Why?
|
| Pregnancy | 1 | 2018 | 7573 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4320 | 0.020 |
Why?
|
| Infant | 1 | 2014 | 13310 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 16273 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 4744 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 5539 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 7551 | 0.000 |
Why?
|